Literature DB >> 19729486

Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice.

Jinhua Li1, Xinli Qu, John F Bertram.   

Abstract

Diabetic nephropathy is the leading cause of chronic renal failure. Myofibroblasts play a major role in the synthesis and secretion of extracellular matrix in diabetic renal fibrosis. Increasing evidence suggests that endothelial cells may undergo endothelial-myofibroblast transition under physiological and pathophysiological circumstances. Therefore, this study investigates whether endothelial-myofibroblast transition occurs and contributes to the development of diabetic renal interstitial fibrosis. Diabetes was induced by administration of streptozotocin to Tie2-Cre;LoxP-EGFP mice, an endothelial lineage-traceable mouse line generated by crossbreeding B6.Cg-Tg(Tek-cre)12F1v/J mice with B6.Cg-Tg(ACTB-Bgeo/GFP)21Lbe/J mice. The endothelial-myofibroblast transition was also studied in MMECs (a mouse pancreatic microvascular endothelial cell line) and primary cultures of CD31+/EYFP- (enhanced yellow fluorescent protein) endothelial cells isolated from adult normal alpha-smooth muscle actin promoter-driven-EYFP (alpha-SMA/EYFP) mouse kidneys. Confocal microscopy demonstrated that 10.4 +/- 4.2 and 23.5 +/- 7.4% of renal interstitial myofibroblasts (alpha-SMA+) in 1- and 6-month streptozotocin-induced diabetic kidneys were of endothelial origin (EGFP+/alpha-SMA+ cells), compared with just 0.2 +/- 0.1% of myofibroblasts in vehicle-treated Tie2-Cre;LoxP-EGFP mice (P < 0.01). Confocal microscopy and real-time PCR showed that transforming growth factor (TGF)-beta1 induced de novo expression of alpha-SMA and loss of expression of VE-cadherin and CD31 in MMECs and primary cultures of renal endothelial cells in a time- and dose-dependent fashion. These findings demonstrate that the endothelial-myofibroblast transition occurs and contributes to the early development and progression of diabetic renal interstitial fibrosis and suggest that the endothelial-myofibroblast transition may be a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729486      PMCID: PMC2751535          DOI: 10.2353/ajpath.2009.090096

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Variegated transgene expression in mouse mammary gland is determined by the transgene integration locus.

Authors:  K W Dobie; M Lee; J A Fantes; E Graham; A J Clark; A Springbett; R Lathe; M McClenaghan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice.

Authors:  Hui John Zhao; Suwan Wang; Huifang Cheng; Ming-zhi Zhang; Takamune Takahashi; Agnes B Fogo; Matthew D Breyer; Raymond C Harris
Journal:  J Am Soc Nephrol       Date:  2006-09-13       Impact factor: 10.121

Review 3.  Targets to retard the progression of diabetic nephropathy.

Authors:  Mark E Cooper; Karin Jandeleit-Dahm; Merlin C Thomas
Journal:  Kidney Int       Date:  2005-10       Impact factor: 10.612

4.  Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy.

Authors:  Takahiko Nakagawa; Waichi Sato; Olena Glushakova; Marcelo Heinig; Tracy Clarke; Martha Campbell-Thompson; Yukio Yuzawa; Mark A Atkinson; Richard J Johnson; Byron Croker
Journal:  J Am Soc Nephrol       Date:  2007-01-03       Impact factor: 10.121

5.  Variegated expression of a globin transgene correlates with chromatin accessibility but not methylation status.

Authors:  D Garrick; H Sutherland; G Robertson; E Whitelaw
Journal:  Nucleic Acids Res       Date:  1996-12-15       Impact factor: 16.971

6.  Embryonic endothelial cells transdifferentiate into mesenchymal cells expressing smooth muscle actins in vivo and in vitro.

Authors:  M C DeRuiter; R E Poelmann; J C VanMunsteren; V Mironov; R R Markwald; A C Gittenberger-de Groot
Journal:  Circ Res       Date:  1997-04       Impact factor: 17.367

7.  Vascular defect beyond the endothelium in type II diabetic patients with overt nephropathy and moderate renal insufficiency.

Authors:  W B Chan; N N Chan; C W K Lai; W Y So; M K W Lo; K F Lee; C C Chow; C Metreweli; J C N Chan
Journal:  Kidney Int       Date:  2006-08       Impact factor: 10.612

8.  Myofibroblasts and arteriolar sclerosis in human diabetic nephropathy.

Authors:  E Pedagogos; T Hewitson; I Fraser; K Nicholls; G Becker
Journal:  Am J Kidney Dis       Date:  1997-06       Impact factor: 8.860

9.  Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression.

Authors:  Masatoshi Jinnin; Hironobu Ihn; Kunihiko Tamaki
Journal:  Mol Pharmacol       Date:  2005-11-15       Impact factor: 4.436

Review 10.  Transgenic animals in medicine: integration and expression of foreign genes, theoretical and applied aspects.

Authors:  Igor L Goldman; Sergei G Kadulin; Sergei V Razin
Journal:  Med Sci Monit       Date:  2004-10-26
View more
  135 in total

Review 1.  Cellular and molecular mechanisms of renal fibrosis.

Authors:  Youhua Liu
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

2.  Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro.

Authors:  Zhaodong Li; Sergio A Jimenez
Journal:  Arthritis Rheum       Date:  2011-08

Review 3.  Vasculopathy in scleroderma.

Authors:  Yoshihide Asano; Shinichi Sato
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

4.  Potassium and ANO1/ TMEM16A chloride channel profiles distinguish atypical and typical smooth muscle cells from interstitial cells in the mouse renal pelvis.

Authors:  Javed Iqbal; Mary A Tonta; Retsu Mitsui; Qun Li; Michelle Kett; Jinhua Li; Helena C Parkington; Hikaru Hashitani; Richard J Lang
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

5.  Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy.

Authors:  Akane Kizu; Damian Medici; Raghu Kalluri
Journal:  Am J Pathol       Date:  2009-09-03       Impact factor: 4.307

Review 6.  Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease.

Authors:  Jianhua He; Yong Xu; Daisuke Koya; Keizo Kanasaki
Journal:  Clin Exp Nephrol       Date:  2013-02-21       Impact factor: 2.801

Review 7.  Inflammatory processes in renal fibrosis.

Authors:  Xiao-Ming Meng; David J Nikolic-Paterson; Hui Yao Lan
Journal:  Nat Rev Nephrol       Date:  2014-07-01       Impact factor: 28.314

8.  TGF-β₁-siRNA delivery with nanoparticles inhibits peritoneal fibrosis.

Authors:  H Yoshizawa; Y Morishita; M Watanabe; K Ishibashi; S Muto; E Kusano; D Nagata
Journal:  Gene Ther       Date:  2015-01-08       Impact factor: 5.250

Review 9.  Renal interstitial fibrosis: mechanisms and evaluation.

Authors:  Alton B Farris; Robert B Colvin
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-05       Impact factor: 2.894

Review 10.  New insights into epithelial-mesenchymal transition in kidney fibrosis.

Authors:  Youhua Liu
Journal:  J Am Soc Nephrol       Date:  2009-12-17       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.